Osteonecrosis of the Jaw in a Patient with Osteoporosis Treated with Oral Bisphosphonates.
10.4055/jkoa.2010.45.2.151
- Author:
Sung Wook CHOI
1
;
Sang Rim KIM
;
Kwang Bok LEE
;
Kwang Woo NAM
;
Kyu Bum SEO
;
Uk NAM
;
Hee Joong KIM
Author Information
1. Department of Orthopedic Surgery, Jeju National University College of Medicine, Jeju, Korea. kimsros@jejunu.ac.kr
- Publication Type:Case Report
- Keywords:
osteoporosis;
osteonecrosis;
bisphosphonate
- MeSH:
Bisphosphonate-Associated Osteonecrosis of the Jaw;
Bone Diseases;
Diphosphonates;
Etidronic Acid;
Female;
Humans;
Jaw;
Osteomalacia;
Osteonecrosis;
Osteoporosis;
Risedronate Sodium
- From:The Journal of the Korean Orthopaedic Association
2010;45(2):151-154
- CountryRepublic of Korea
- Language:Korean
-
Abstract:
Bisphosphonates are widely used in the management of metastatic bone disease and in the prevention of osteomalacia and osteoporosis. In particular, oral preparations are more commonly used for the prevension and treatment of osteoporosis. Bisphosphonate-related osteonecrosis of the jaws (BRONJ) has been well documented recently in relation to intravenous preparations of the drug. But, a few cases have been reported of oral bisphosphonate-associated osteonecrosis. We could not find any risedronate cases in the Korean medical literature. Here we report a case of BRONJ in a 91-year-old woman patient receiving an oral bisphosphonate (risedronate) for the treatment of osteoporosis.
